Episode Details

Lyme disease cases in Canada have surged from 144 in 2009 to over 7,000 in 2025, driven by infected blacklegged ticks and causing everything from fatigue to life-threatening complications. After the only previous vaccine, LYMErix, was withdrawn in 2002 due to safety concerns and low demand, new hope arrives: Pfizer and Valneva’s vaccine showed 70% efficacy in trials, with Pfizer preparing for regulatory approval. Moderna is also testing two vaccines in Phase 2. While promising, experts warn hurdles like cost, convenience, and public trust may slow adoption. For now, prevention through clothing, repellents, and tick removal remains critical—and early antibiotic treatment works if symptoms appear.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/400d4921c2bd6f37